Institute of Biomedicine, University of Turku and Department of Pathology, Turku University Hospital, Kiinamyllynkatu 10, 20520 Turku, Finland.
University of Turku, Department of Pulmonary Diseases and Clinical Allergology and Division of Medicine, Department of Pulmonary Diseases, Turku University Hospital, Hämeentie 11, 20521 Turku, Finland.
Neoplasia. 2020 Sep;22(9):333-342. doi: 10.1016/j.neo.2020.05.004. Epub 2020 Jun 22.
Tumor mutation burden (TMB) is an emerging predictive cancer biomarker. Few studies have addressed the prognostic role of TMB in non-small cell lung carcinoma, with conflicting results. Moreover, the association of TMB with different histological subtypes of lung adenocarcinoma has hitherto not been systematically evaluated. Here we studied the prognostic value of TMB and its distribution in different histological subtypes of lung adenocarcinomas in a retrospective cohort using the most recent updated classification guidelines.
176 surgically resected stage I-IV lung adenocarcinomas were histologically reclassified according to WHO 2015 guidelines. A modified classification subdividing the acinar subtype into classic acinar, complex glandular and cribriform subtypes was further applied and potentially prognostic histopathological characteristics such as tumor-infiltrating lymphocytes were evaluated. 148 patients with stage I-III tumors and complete follow-up data were included in the survival analyses. TMB was determined by a commercial next generation sequencing panel from 131 tumors, out of which 105 had survival data available.
Predominant micropapillary, solid and complex glandular as well as nonpredominant cribriform histological subtypes were associated with significantly shorter survival. High TMB concentrated in micropapillary, solid and acinar predominant subtypes. Interestingly, TMB ≥ 14 mutations/MB conferred a stage- and histology-independent survival benefit compared to TMB < 14 in multivariable analysis for overall (HR 0.284, 95% CI 0.14-0.59, P=0.001) and disease-specific survival (HR 0.213, 95% CI 0.08-0.56, P=0.002).
TMB was an independent biomarker of favorable prognosis in our cohort of lung adenocarcinoma despite being associated with predominant histological subtypes considered aggressive.
肿瘤突变负担(TMB)是一种新兴的癌症预测生物标志物。少数研究探讨了 TMB 在非小细胞肺癌中的预后作用,结果存在争议。此外,TMB 与肺腺癌不同组织学亚型的相关性尚未得到系统评估。本研究使用最新的分类指南,在回顾性队列中研究了 TMB 及其在肺腺癌不同组织学亚型中的分布的预后价值。
根据 2015 年世卫组织指南对 176 例手术切除的 I-IV 期肺腺癌进行了组织学重新分类。进一步应用了一种改良分类,将腺泡亚型细分为经典腺泡、复杂腺体和筛状亚型,并评估了潜在的预后组织病理学特征,如肿瘤浸润淋巴细胞。对 148 例 I-III 期肿瘤且具有完整随访数据的患者进行了生存分析。从 131 例肿瘤中通过商业下一代测序面板确定了 TMB,其中 105 例有生存数据。
主要的微乳头状、实体和复杂腺体以及非主要的筛状组织学亚型与生存显著缩短相关。高 TMB 集中在微乳头状、实体和腺泡为主的亚型中。有趣的是,与 TMB<14 相比,在多变量分析中,TMB≥14 个突变/MB 在总生存(HR 0.284,95%CI 0.14-0.59,P=0.001)和疾病特异性生存(HR 0.213,95%CI 0.08-0.56,P=0.002)方面具有独立的生存获益,且与分期和组织学无关。
尽管 TMB 与被认为具有侵袭性的主要组织学亚型相关,但在我们的肺腺癌队列中,TMB 是预后良好的独立生物标志物。